高龄老年人甲状腺功能检测正常参考值

目的确立80岁以上老年人甲状腺功能正常参考值：方法健康老人81名,分为A组80～89岁高龄老人52名,B组印～69岁老人29名。测定各组血清中三碘甲状腺原氨酸(TT3)、血清总甲状腺素(TT4)、血清游离甲状腺素(FT4)、血清游离三碘甲状腺原氨酸(FT3)及促甲状腺激素(TSH)的含量。结果和结论 80岁以上老年人血TT3为1.22～2．52nmol／L,TT4为59．31～152．49nmol／L,FT4为11．11～22．51pmol／L,FT3为3．28～5．75pmol／L;80岁以上老年男性TSH为0.8～4．2mU/L．女性TSH为0．7-6．1mU/L。     

急性乙型肝炎患者血清甲状腺激素水平变化

目的研究急性乙型肝炎患者血清中甲状腺激素水平变化情况,观察患者甲状腺激素水平的动态变化和甲状腺激素水平异常与发病时间的关系。方法急性乙型肝炎患者36例作为观察对象,健康体检的36人作为对照组。检测其入院时的甲状腺激素水平：血清总甲状腺素（TT4）、血清总三碘甲腺原氨酸（TT3）、血清游离甲状腺素（FT4）、血清游离三碘甲腺原氨酸（FT3）、促甲状腺激素（TSH）,并与对照组比较。对异常者1周后复查甲状腺激素水平,以后每周复查1次,直至正常,观察其动态变化。结果急性乙型肝炎患者血清甲状腺激素TT4、TT3、FT4、FT3水平较对照组增高,差异具有统计学意义（P〈0.05）。TSH较对照组降低,但TSH均在正常值范围内,差异无统计学意义（P〉0.05）。入院时TT4、TT3、FT4、FT3高于正常值者在第三周全部转为正常。结论急性乙型肝炎患者血清甲状腺激素TT4、TT3、FT4、FT3水平升高,对于升高超过正常值者不需要治疗,随着肝功能逐渐好转,短期可恢复正常。     

熊去氧胆酸治疗原发性胆汁性胆管炎患者血清甲状腺激素水平变化*

目的 探讨应用熊去氧胆酸（UDCA）治疗原发性胆汁性胆管炎患者血清甲状腺激素水平的变化。方法 2016年1月~2017年6月我院治疗的原发性胆汁性胆管炎患者70例和原发性胆汁性肝硬化患者95例,另选20例健康人作为对照组。给予患者UDCA治疗3月,检测治疗前后血清甲状腺激素水平变化。结果 在治疗3个月末,两组患者肝功能指标得到改善,除胆管炎患者血清ALP和GGT水平仍显著高于肝硬化患者外,其他肝功能指标比较,差异无统计学意义（P>0.05）;治疗前,胆管炎患者血清总三碘甲状腺原氨酸（TT3）、总甲状腺素（TT4）、游离三碘甲状腺原氨酸（FT3）和游离甲状腺素（FT4）水平分别为1.6±0.2 nmol/L、3.2±0.4 pmol/L、95.6±28.7 nmol/L和10.3±3.6 pmol/L,肝硬化患者分别为1.1±0.2 nmol/L、3.0±0.3 pmol/L、88.2±26.7 nmol/L和9.7±2.5 pmol/L,均显著低于健康人【分别为（2.5±0.5 nmol/L、4.7±0.8 pmol/L、115.7±31.6 nmol/L和13.8±4.1 pmol/L,P<0.05】,两组患者血清促甲状腺素（TSH）水平与健康人比,差异无统计学意义【分别为（2.9±0.5 mIU/L和 2.9±0.7 mIU/L对 3.3±0.6 mIU/L,P>0.05】; 在治疗3个月末,胆管炎患者血清TT3、FT3、TT4和FT4水平分别为2.4±0.6 nmol/L、4.5±0.8 pmol/L、108.2±36.2 nmol/L和12.9±3.5 pmol/L,较治疗前显著上升,已与健康人无统计学差异（P>0.05）,而肝硬化患者血清TT3、FT3、TT4和FT4水平分别为1.2±0.3 nmol/L、3.4±0.4 pmol/L、93.7±29.8 nmol/L和9.9±3.1 pmol/L,无明显改善,仍显著低于健康人（P<0.05）。结论 原发性胆汁性胆管炎患者经熊去氧胆酸治疗后,血清甲状腺激素水平可获得改善,因此应该早期诊断、早期治疗。     

T4自身抗体的存在干扰游离T4的测定

最近我们在使用美国DPC公司生产的Coat-A-Count FT_4药盒时遇见一例因血清T_4自身抗体干扰血清FT_4测定,测定结果显示FT_4假性升高。现将这例研究结果报告如下。 一、对象:1例慢性淋巴细胞性甲状腺炎（慢甲炎）、甲状腺功能减退症患者,女,46岁。甲状腺功能检查结果显示:总甲状腺素（TT_4）<26nmol/L,总三碘甲状腺原氨酸（TT_3）1.2nmol/L,游离甲状腺素（FT_4）>124pmol/L,游离三碘甲状腺原氨酸（FT_3）3.7pmol/L,促甲状腺激素（TSH）47.2mU/L,甲状腺球蛋白抗体（TGA）62.2％,微粒体抗体（MCA）59.5％。多次血清甲状腺激素测定值见附表。     

甲状腺功能亢进症合并急性非淋巴细胞白血病-M3一例

患者,女性,27岁.因“心慌、手抖、怕热、多汗2个月”入院.病初有心悸、手抖、怕热、多汗,双眼酸胀、干涩,甲状腺Ⅲ度肿大,伴血管杂音.外院给予“甲巯咪唑、心得安”治疗,效果不佳.患者入院前1周受凉后出现咳嗽、咳痰,有牙龈出血.门诊检查甲状腺功能结果显示：总三碘甲状腺原氨酸（TT3）正常,总甲状腺素（TT4） 387.0 nmol/L,游离三碘甲状腺原氨酸（FT3）40.8pmol/L,游离甲状腺素（FT4）100.8 pmol/L,高敏促甲状腺素（HS-TSH）0.01 mU/L;血常规示：WBC 1.7×10^9/L,PLT 17×10^9/L.     

肢端肥大症伴甲状腺多发结节一例

患者,女, 41岁,因“面部改变伴手指、足趾增粗 4年”入院。入院体检:Bp120 /80mmHg,颧骨、眉弓、下颌突出,鼻大,口、唇、舌体肥厚,手足粗大、皮肤增厚粗糙,手臂、背、臀、面部痤疮多发,语音低沉,无视野缺损。甲状腺未触及肿大,心肺体检无殊。辅助检查:血清基础生长激素(GH) >40μg/L,明显高于正常。葡萄糖抑制试验血浆GH不能被抑制。甲状腺功能全套:总甲状腺素(TT4 ) 55. 5nmol/L(正常范围 58. 0 ~161. 0nmol/L),游离三碘甲腺原氨酸 (FT3 ) 2. 70pmol/L(正常范围3. 23 ~7. 22pmol/L)、游离四碘甲腺原氨酸(FT4 )8. 90pmol/L(正常…     

慢性阻塞性肺疾病患者血清甲状腺激素的变化及临床意义

目的探讨慢性阻塞性肺疾病（COPD）患者血清中甲状腺激素的变化及临床意义。方法采用放射免疫法（RIA）检测46例COPD患者及32例正常对照血清中三碘甲状腺原氨酸（TT3）、甲状腺素（TT4）、游离三碘甲状腺原氨酸（FT3）、游离甲状腺素（FT4）、促甲状腺素（TSH）及反三碘甲状腺原氨酸（rT3）6项指标。结果COPD患者的TT3、TT4、FT3水平显著降低，随着呼吸衰竭，甲状腺激素水平进一步降低，FT4也明显低于对照组，rT3则显著高于对照组，TSH无明显改变。结论监测COPD患者血清甲状腺激素水平可判断COPD的危重程度及估计预后。     

碘缺乏对BALB/c小鼠促甲状腺激素β剪接变体基因表达的影响

目的 制备碘缺乏小鼠模型,检测促甲状腺激素(TSH)β剪接变体(TSHβ-Ⅴ)是否受循环中甲状腺激素的调节,探讨免疫系统来源的TSHβ-Ⅴ在维持甲状腺自稳态中的作用.方法 选用离乳BALB/c小鼠20只,雌雄各半.小鼠按体质量和性别随机分为2组,每组10只.对照组:饮去离子水,普通饲料喂养;低碘组:饮去离子水,低碘饲料(含碘量20 - 40μg /kg)喂养,每日碘摄入量约为0.25μg/d.3个月后处死小鼠,化学发光免疫分析法(CIA)检测小鼠血清中甲状腺激素和TSH水平,实时定量(RT)-PCR法测定小鼠骨髓、外周血、甲状腺、垂体TSHβ-Ⅴ的表达.结果 低碘组小鼠血清总甲状腺素(TT4)、游离甲状腺素(FT4)、总三碘甲腺原氨酸(TT3)、游离三碘甲腺原氨酸(FT3)[ (0.47±0.70)nmol/L、(2.41±0.28)pmol/L、(0.76±0.08 )nmol/L、(4.01±0.40) pmol/L]显著低于对照组[(55.2±3.68)nmol/L、(32.72±1.02) pmol/L、(1.10±0.06)nmol/L、(5.40±0.38 )pmol/L,t=43.81、86.04、9.81、7.51,P均＜0.01];低碘组小鼠TSH[(35.67±17.39)mU/L]明显高于对照组[(0.24±0.10)mU/L,t =-6.11、,P＜0.001];低碘组小鼠骨髓、外周血TSHβ-Ⅴ mRNA表达水平[(9.62±0.60)、(9.25±0.83)]均低于正常对照组(7.69±0.36、7.11±0.41,t=6.77、5.64,P均＜0.001);低碘组小鼠甲状腺TSHβ-Ⅴ mRNA表达(9.32±0.91)与对照组(9.12±0.62)相比较,差异无统计学意义(t=0.45,P＞0.05);在骨髓、外周血、甲状腺未检出天然型TSHβ;垂体中TSHβ-Ⅴ mRNA和天然型TSHβ表达水平(1.99±0.61、- 7.17±1.78)均高于对照组(5.75±0.98、-1.43±0.51,t=-8.02、- 7.60,P均＜0.01].结论 低碘饮食引发小鼠甲状腺功能低下,抑制骨髓和外周血TSHβ-Ⅴ mRNA的表达,提示免疫系统来源的TSHβ-Ⅴ可能具有比天然型TSHβ更重要的免疫-甲状腺调节作用.     

甲状腺激素与糖尿病病情及程度的相关性研究

目的分析研究甲状腺激素与糖尿病病情及程度的相关性。方法将自2013年3月—2014年3月期间在该院诊断治疗的30例糖尿病患者设置为糖尿病组,测定患者的血清空腹血糖、促甲状腺激素(TSH)、甲状腺素(TT4)以及三碘甲腺原氨酸(TT3)水平。并且将30例健康体检者设定为正常对照组,进一步探究甲状腺激素与糖尿病病情及程度的相关性,为糖尿病患者的临床治疗提供参考。结果两组患者甲状腺素(TT4)水平差异无统计学意义(P0.05);两组患者血清空腹血糖、促甲状腺激素(TSH)以及三碘甲腺原氨酸(TT3)水平差异有统计学意义(P0.05)。结论甲状腺激素与糖尿病病情及程度呈正相关关系,即:甲状腺激素下降,糖尿病患者的患病程度越轻,病情较容易控制。     

左旋甲状腺素在甲状腺功能减退症合并高脂血症治疗中的应用

目的观察左旋甲状腺素在甲状腺功能减退症合并高脂血症治疗中的应用效果。方法对68例甲状腺功能减退症合并高脂血症患者采用左旋甲状腺素治疗,观察治疗前后血清游离三碘甲腺原氨酸(FT3)、游离甲状腺素(FT4)、超敏促甲状腺激素(TSH)和血清甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白(LDL)及高密度脂蛋白(HDL)水平变化。结果本组患者治疗前血清FT3为(2.19±0.72)pmol/L,FT4为(6.87±1.26)pmol/L,TSH为(86.42±9.53)mU/L,TG为(2.23±0.52)mmol/L,TC为(6.16±1.54)mmol/L,LDL为(3.56±0.41)mmol/L,HDL为(1.02±0.34)mmol/L;治疗后分别为(5.17±1.82)pmol/L、(19.15±6.93)pmol/L、(2.25±1.13)mU/L及(1.14±0.29)、(4.82±1.07)、(2.72±0.28)、(1.32±0.57)mmol/L;治疗后各指标与治疗前比较,P均<0.05。结论左旋甲状腺素治疗甲状腺功能减退症合并高脂血症,既可改善甲状腺功能指标,又能降低血脂水平。     

二甲双胍对促甲状腺素影响的初步研究

目的 观察二甲双胍对血清促甲状腺素(TSH)的影响.方法从2型糖尿病患者中,入选原发性甲状腺功能减退症(甲减)患者48例,组1单用二甲双胍而未予左旋甲状腺素(L-T4)替代治疗(n=17),组2给予L-T4稳定替代量的同时加用二甲双胍(n=19),组3用L-T4稳定替代量和非二甲双胍的其他降糖药(n=12).另外20例甲状腺功能正常的其他甲状腺疾病患者(组4)和30例无甲状腺疾病的患者(组5)作为对照.各组患者均定期检测血清TSH、FT3、FT4、TT3、TT4及血糖等主要指标的变化.结果 治疗12个月与基线时比较,组1为(5.05±1.07)对(2.61±0.91)mU/L(P＜0.01),组2为(2.67±1.03)对(1.35±0.74)mU/L(P＜0.01),两组的FT3及FT4均无明显变化.15例TSH显著降低的患者中有13例(87%)在停用二甲双胍后8～12周内TSH由(1.30±0.71)回升至(2.58±1.02)mU/L(P＜0.01).组3、组4及组5的血清TSH和甲状腺激素的水平均无明显改变.结论 服用二甲双胍可使TSH下降.

Abstract：

Objective To evaluate the effects of metformin on thyrotropin(TSH)levels. Methods From the patients with type 2 diabetes mellitus or metabolic syndrome, 48 patients with primary hypothyroidism were enrolled and grouped. 17 patients were treated only with metformin(group A), 19 patients with metformin and stable L-T4substitution(group B), and the remaining 12 patients with antidiabetic drugs(other than metformin)and L-T4(group C). Meanwhile, 20 euthyroid patients with other thyroid abnormalities(group D)and 30 patients without thyroid diseases(group E)served as control. TSH, FT3, FT4, TT3, TT4, and blood glucose were determined regularly in all these subjects. Results After administration of metformin for 12 months, serum TSH were decreased in group A [(5.05±1.07 vs 2.61±0.91)mU/L, P＜0.01] and group B [(2.67±1.03 vs 1.35±0.74)mU/L, P＜0.01]. No difference was found in FT3and FT4in both groups. TSH levels were raised from(1.30±0.71)to(2.58±1.02)mU/L(P＜0.01)within 8～12 weeks in 13 out of 15 patients after metformin withdrawal. Serum TSH and thyroid hormones in the other 3 groups were not significantly changed. Conclusion Administration of metformin may lead to reduction of serum TSH level.     

Transient elevation of triiodothyronine caused by triiodothyronine autoantibody associated with acute Epstein-Barr-virus infection.

A unique 16-year old female patient presented after acute Epstein-Barr virus (EBV) infection with severe primary hypothyroidism. Her thyroid test results were thyrotropin level (TSH) of 198 mU/L (normal, 0.4-4 mU/L), free thyroxine [FT(4)], 2.5 pmol/L (normal, 10-25 pmol/L), total triiodothyronine (TT(3)) > 19.5 nmol/L (normal, 1.3-2.7 nmol/L), and free triiodothyronine (FT(3)), 0.77 pmol/L (normal, 3.3-6.3 pmol/L). She had high titers of thyroglobulin and thyroid peroxidase autoantibodies. In vitro triiodothyronine (T(3))-binding measured by radioimmunoprecipitation was 86% (normal, up to 8.5%) and thyroxine (T(4))-binding 8.2% (normal, 6.4%). Serum immunoglobulin G (IgG) absorption, achieved by protein-G Sepharose beads, decreased TT(3) toward normal. Levothyroxine treatment normalized the low baseline FT(4) and FT(3) values, and suppressed TSH to normal. However, TT(3) remained highly elevated and returned to normal after 20 months, while T(3 )binding gradually decreased. Thus, her severe hypothyroidism was masked by this unusual phenomenon. Thirty-four patients with EBV infection (15 with acute disease and 19 with previous infection) were tested for thyroid hormone levels. EBV antibodies (early antigen immunoglobulin M [IgM] and IgG and anti-Epstein-Barr virus nuclear antigen [EBNA] IgG) were measured by enzyme-linked immunosorbent assay (ELISA). In 15 patients with acute EBV the mean TT(3) level was 2.47 +/- 0.39 nmol/L (5 had TT(3) values above normal) compared to a mean TT(3) of 1.70 +/- 0.53 nmol/L in 19 subjects with previous infection (p < 0.0005; only 1 had a TT(3) result above normal), with no differences in FT(4) and TSH concentrations between the two groups. Acute EBV infection may be associated with transient mild to severe TT(3) elevation as a result of assay interference by anti-T(3) autoantibodies.     

2型糖尿病患者甲状腺功能与纤维蛋白原关系的研究

目的 探讨T2DM患者甲状腺功能与纤维蛋白原（FIB）的相关性. 方法 选取T2DM患者502例,测定FIB、游离三碘甲腺原氨酸（FT3）、游离甲状腺素（FT4）、促甲状腺激素（TSH）和临床生化指标,采用方差分析、Spearman相关分析及多元逐步回归分析甲状腺功能与FIB的相关性. 结果 （1）FT3与FIB呈负相关（r=-0.331,P＜0.01）.（2）甲减组FIB高于甲亢组[（3.765±1.089）vs（3.346±0.879）pmol/L,P＜0.01],与正常组[（3.232±0.985） pmol/L]比较差异无统计学意义;按FIB由低到高四分位间距分组,FT3依次为（4.54±0.96）,（4.47±0.81）,（3.94±1.13）及（3.67±0.95）pmol/L,P0～组与P25～组均高于P75～组（P＜0.01）.（3）年龄、[脂蛋白LP-（a）]、C-RP、HbA1c是FIB的独立影响因素（β=0.382,0.272,0.552,0.221;P＜0.05或P＜0.01）;FT3与FIB呈负相关（β=--0.289,P＜0.01）,且与C-RP呈依赖性. 结论 T2DM患者年龄、LP-（a）、C-RP、HbA1 c及FT3均与FIB相关,甲状腺激素可能通过炎症机制影响FIB.     

The influence of caloric deprivation and food composition on TSH, thyroid hormones and nuclear binding of T3 in mononuclear blood cells in obese women

In vivo changes in thyroid-stimulating hormone (TSH), thyroxin (T4), triiodothyronine (T3) and nuclear binding of T3 (NBT3) in mononuclear blood cells were studied in obese women during seven days of caloric deprivation (maximum 1,100 kcal/d). In seven women given a high protein diet (80% protein, 7% carbohydrates, 7% fat) and in two women who fasted (group 1), total T3 (TT3) decreased from 1.66 +/- 0.43 nmol/L to 1.11 +/- 0.32 nmol/L (P less than .01), free T3 (FT3) decreased from 5.7 +/- 1.1 pmol/L to 4.3 +/- 1.6 pmol/L (P less than .01), and free T4 (FT4) increased from 17.8 +/- 2.3 pmol/L to 21.1 +/- 2.0 pmol/L (P less than .01). In five women given a carbohydrate diet (Dextrin-maltose 100%) (group 2), thyroid hormones were unchanged, TT3 was at start 1.66 +/- 0.24 nmol/L and after seven days 1.43 +/- 0.26 nmol/L (NS), FT3 changed from 6.4 +/- 1.8 pmol/L to 6.0 +/- 2.1 pmol/L (NS) and FT4 changed from 20.4 +/- 5.1 pmol/L to 20.6 +/- 3.1 pmol/L (NS). The caloric intake and the weight reduction was the same in the two groups. Basal TSH and TSH after thyrotropin-releasing hormone (TRH) (TSH+30min) declined in both groups. In group 1, basal TSH declined from 1.88 +/- 1.07 microU/mL (P less than .03), and TSH+30min declined from 12.44 +/- 7.49 microU/mL to 9.38 +/- 5.97 microU/mL (P less than .03). In group 2, basal TSH declined from 2.09 +/- 0.87 microU/mL to 1.66 +/- 0.92 microU/mL (P less than .03), and TSH+30min declined from 15.63 +/- 7.90 microU/mL to 11.93 +/- 7.20 microU/mL (NS).(ABSTRACT TRUNCATED AT 250 WORDS)     

Thyrotropin suppression by thyroid hormone replacement is correlated with thyroxine level normalization in central hypothyroidism.

We have retrospectively studied 41 patients with hypothalamic-pituitary disease and central hypothyroidism associated with hypopituitarism. Sixteen patients had nonsecreting pituitary macroadenoma, whereas different sellar and suprasellar pathologies affected all other patients. Pretreatment thyrotropin (TSH) level (mean +/- standard error of the mean [SEM]) was 2.04 +/- 0.25 mU/L (normal, 0.4-4), and gradually decreased to 0.51 +/- 0.19 mU/L (range, 0.009-3.38) by treatment with levothyroxine in a mean dose of 86 +/- 6 microg/d. TSH was suppressed by thyroid replacement to less than 0.5 mU/L in 80% of patients. Mean baseline free thyroxine (FT4) was 7.55 +/- 0.51 pmol/L (normal, 11.8-24.6) and gradually increased with thyroid hormone to 15.19 +/- 1.0 pmol/L, whereas total thyroxine (TT4) increased from 57.4 +/- 2.6 to 104.4 +/- 5.0 nmol/L (normal, 77-154). Mean pretreatment total triiodothyronine (TT3) was 1.44 +/- 0.09 nmol/L (normal, 1.1-2.7), and was not altered by treatment. Thyrotropin-releasing hormone (TRH) test was performed in 20 patients before thyroid replacement, and mean baseline and peak TSH levels were 1.33 +/- 0.3 and 7.14 +/- 1.62 mU/L, respectively. In 5 subjects TSH was stimulated to 6 mU/L or more, whereas in 5 others TSH was not affected. Based on linear regression of logarithm (Ln) TSH against FT4, a leftward shift of the TSH/FT4 ratio was demonstrated in patients with central hypothyroidism compared to 17 patients with primary hypothyroidism. Plotting measurements of TSH against FT4 for 6 individuals with central hypothyroidism showed different regression slope for each patient. Suppression of TSH by thyroid replacement to levels below 0.1 mU/L predicted euthyroidism in 92% of cases, compared to 34% when TSH was above 1 mU/L (p < 0.0001). In conclusion, in central hypothyroidism baseline TSH is usually within normal values, and is further suppressed by exogenous thyroid hormone as in primary hypothyroidism, but to lower levels. Thus, insufficient replacement may be reflected by inappropriately elevated TSH levels, and may lead to dosage increment.     

老年人血管性痴呆与甲状腺轴功能关系的研究

目的　探讨老年人血管性痴呆（VD）与甲状腺轴功能的关系。　方法　采用放射免疫分析法检测31例VD患者、22例不伴有痴呆的脑血管病（CVD）患者及22例同龄对照的血清三碘甲状腺原氨酸（T     

干燥综合征合并桥本甲状腺炎的临床特点及相关因素分析

目的 分析干燥综合征（SS）合并桥本甲状腺炎（HT）患者的临床表现、特点以及相关因素。方法 回顾性分析32例SS合并HT住院患者和24例随机抽样的SS对照组患者的资料。结果 合并HT的SS患者眼干、甲状腺增大及浆膜腔积液的发病率显著高于SS对照组。与SS对照组相比，SS合并HT患者血清甘油三酯水平显著增高．血清IgA及α1球蛋白比例显著降低。所有SS患者的血清C反应蛋白（CRP）与血清三碘甲状腺原氨酸（T3）、甲状腺素（T4）、游离甲状腺素（FT4）水平呈显著负相关，与促甲状腺激素（TSH）、抗甲状腺球蛋白抗体（ATG）呈显著正相关；血清胆固醇水平与血清游离三碘甲状腺原氨酸（FIB）、FT4水平呈显著负相关，血糖水平与血清TSH、ATG水平呈显著负相关；血清IgG水平与血清T4、FT3水平呈显著正相关，血清C4水平与血清TSH、ATG及抗甲状腺髓过氧化酶抗体（ATM）水平呈显著负相关；血清α2球蛋白比例与血清T4呈显著正相关；血清γ球蛋白比例与血清ATG水平呈显著正相关。结论 SS患者易合并HT，当SS患者临床出现眼干明显、甲状腺增大、浆膜腔积液，CRP、甘油三酯、胆固醇及γ球蛋白升高，血糖、IgA、IgG、C4、cd及以球蛋白水平下降时，需警惕合并HT。     

碘/钠摄入量对小鼠血脂代谢影响的实验研究

目的 探讨膳食碘摄入量对适钠和低钠饮食小鼠血脂代谢影响,为揭示碘与心血管疾病发病的相关性进行初步研究.方法 Balb/c小鼠260只,按体质量、性别随机分为适钠组(Na)和低钠组(Lna),每组130只;此两大组又分别按照碘摄入量分为①重度低碘组(SID);②轻度低碘组(MID);③适碘组(NI);④10倍碘过量组(10HI);⑤50倍碘过量组(50HI),总计为10组,每组26只.各组小鼠在饲养8个月时收集尿液和小鼠外周血,分离血清.测定小鼠尿碘、体质量、血脂[甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白(LDL)、高密度脂蛋白醇(HDL)]及甲状腺激素水平[总甲状腺素(TT4),总三碘甲腺原氨酸(TT3)、游离甲状腺素(FT4)、游离三碘甲腺原氨酸(FT3)].结果适钠组中,SID组、MID组雄性小鼠TG水平[(1.64±0.35)、(1.67±0.31)mmol/L]和SID组TC水平[(3.88±0.35)mmol/L]明显高于NI组[(1.49±0.42)、(3.25±0.47)mmol/L,P均＜0.05],SID组中雌性小鼠TG水平[(1.52±0.22)mmol/L]高于NI组[(1.23±0.22)mmol/L,P＜0.05].10HI和50HI组雄性小鼠外周血TG水平[(1.16±0.23)、(1.21±0.27)mmol/L]低于NI组(P均＜0.05),雌性小鼠TC水平[(2.37±0.49)、(2.48±0.37)mmol/L)低于NI组[(2.84±0.37)mmol/L,P均＜0.05].在低钠组,SID组雄性小鼠TG、TC水平[(1.39±0.40)、(3.33±0.46)mmol/L]均高于NI组[(1.30±0.28)、(3.00±0.53)mmol/L,P均＜0.05],SID组雌性小鼠TG、TC、LDL水平[(1.48±0.26)、(276±0.43)、(0.62±0.22)mmol/L]、MID组雌性小鼠LDL水平[(0.60±0.17)mmol/L]均高于NI组[(1.22±0.36)、(2.51±0.38)、(0.48±0.08)mmol/L,P均＜0.05].10HI和50HI组雄性小鼠TG水平[(1.12±0.22)、(0.90±0.11)mmol/L]均低于NI组(P均＜0.05),10HI和50HI组雌性小鼠TC水平[(2.35±0.34)、(2.37±0.37)mmol/L]、50HI组雌性小鼠LDL水平[(0.65±0.18)mmol/L]均低于NI组(P均＜0.05).适钠组中的SID和MID组血清TT4[(0.00±0.00)、(17.15±15.26)nmol/L]、FT4[(0.93±0.42)、(18.46±4.31)pmol/L]和TT3[(0.49±0.07)、(0.67±0.10)nmol/L]、FT3[(2.86±0.37)、(3.18±0.24)pmol/L]水平均低于NI组[(37.15±15.26)、(28.46±4.31)、(0.85±0.10)、(3.87±0.24)pmol/L,P＜0.01或P＜0.05].在低钠组,SID和MID组血清TT4、FT4和TT3、FT3水平[(0.00±0.00)nmol/L、(1.03±0.78)pmol/L、(0.51±0.05)nmol/L,(3.01±0.17)pmol/L,(19.76±12.22)nmol/L、(21.46±5.37)pmol/L、(0.71±0.21)nmol/L、(3.56±0.23)pmol/L]均低于NI组[(36.23±14.72)nmol/L、(30.96±6.33)pmol/L、(0.89±0.20)nmol/L、(4.05±0.24)pmol/L,P均＜0.05],10HI组的TT3水平[(1.06±0.23)nmol/L]高于NI组(P＜0.05).结论碘缺乏可致TG、TC和LDL升高,过量碘可致TG/TC水平降低.碘摄入量是影响血脂代谢的重要因素.限盐饮食的同时,严密监控碘的摄入量对当前有效防治心血管疾病应具有重要作用.